Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $64,736.64 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 101,151 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $0.64, for a total value of $64,736.64. Following the completion of the transaction, the insider owned 406,282 shares in the company, valued at approximately $260,020.48. This trade represents a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 4.3%

HOWL stock traded down $0.03 during trading on Tuesday, reaching $0.63. The stock had a trading volume of 500,207 shares, compared to its average volume of 436,209. The firm has a market cap of $30.71 million, a PE ratio of -0.51 and a beta of 0.41. The stock’s 50 day moving average is $0.81 and its two-hundred day moving average is $0.84. Werewolf Therapeutics, Inc. has a 52 week low of $0.53 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HOWL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HOWL. Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the period. Vanguard Group Inc. lifted its position in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares during the period. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $409,000. Finally, Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics in the 3rd quarter worth approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.